Emergent Stability Testing for HIV Adenoviral Vaccine Candidates

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTE OF HEALTH NIH-OD

Contract Value

Not provided

Codes & Classification
Solicitation Number

NOI-NIAID-26-0001

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

Q301

Additional Details
Set Aside

None

Place of Performance

Rockville, Maryland, UNITED STATES

SourceSAM
Documents1
The National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH) under the Department of Health and Human Services, has issued a presolicitation notice (NOI-NIAID-26-0001) announcing its intent to award a sole source, firm-fixed price purchase order to Emergent Product Development Gaithersburg Inc. The purpose of this procurement is to ensure the continued maintenance and regulatory compliance of critical Biologics Master Files (BB-MF 018816 and BB-MF 14883) associated with HIV-1 adenoviral vaccine candidates. This acquisition supports the ongoing stability testing and regulatory stewardship of the Biologics Master File 018816, which contains Chemistry, Manufacturing, and Controls (CMC) and nonclinical study data for the Human Immunodeficiency Virus Type 1, Recombinant (Adenovirus Type 4; Ad4Env150KN and Ad4-Env145FL; 1086 clade C Env; A549 Cells) Vaccines, Live. The stability testing is essential for maintaining the integrity of the Investigational New Drug (IND) application 030255, enabling NIAID to continue its research and development efforts in HIV vaccine candidates. Although Emergent is no longer directly conducting the stability testing, it retains ownership of the master file, which must remain open and current for regulatory purposes. Additionally, Emergent is responsible for the maintenance of Biologics Master File 14883, which pertains to the manufacture and characterization of the A549 Master Cell Bank, a key component in the production of the PXVX0329 drug substance. Emergent will fund and submit the required annual reports for BB-MF 14883 from October 2025 through October 2029, ensuring ongoing compliance and facilitating collaboration between NIAID and its contractors. The period of performance for this requirement is structured as follows: a base period from April 27, 2026, to March 31, 2027, with two option years extending through March 31, 2029. Notably, there is a lapse in coverage from October 1, 2025, to April 26, 2026; the new period of performance will reinstate coverage, and this reinstatement will be reflected in the contract pricing. This procurement is classified under NAICS code 541714 (Research and Development in Biotechnology, except Nanobiotechnology), with a Product Service Code of Q301 (Medical – Laboratory Testing). The place of performance is Rockville, Maryland. The notice specifies that this is not a solicitation for competitive quotations. The Government intends to negotiate solely with Emergent Product Development Gaithersburg Inc., as it is the only entity with access to and ownership of the required Biologics Master Files. However, interested parties who believe they possess the requisite capabilities may submit a detailed capabilities statement within ten days of the notice’s publication. Such submissions will be evaluated solely to determine if a competitive procurement is warranted. There are no set-aside requirements for this procurement, and Emergent Travel Health Inc. is identified as a large business. The contracting office is located at 5601 Fishers Lane, Rockville, MD 20852. The primary point of contact for this opportunity is Linda E. Smith, Contracting Officer, who can be reached at [email protected]. This notice fulfills the requirements of FAR 5.101(a)(1) for publicizing proposed contract actions and outlines the Government’s intent to proceed with a sole source award unless a qualified alternative source is identified. The Government reserves the right to use information provided by respondents as deemed necessary and is under no obligation to acknowledge or provide feedback on submissions. For further details or to express interest, contractors should refer to the official notice on SAM.gov (Opportunity ID: 6dc6b782e7734be1b1d7176a011c67a5).